Journal
ARCHIVES OF NEUROLOGY
Volume 69, Issue 10, Pages 1255-1258Publisher
AMER MEDICAL ASSOC
DOI: 10.1001/archneurol.2012.540
Keywords
-
Categories
Funding
- NIA NIH HHS [R21 AG047484] Funding Source: Medline
- NINDS NIH HHS [U01 NS074501] Funding Source: Medline
Ask authors/readers for more resources
Although significant progress has occurred in the past 20 years regarding our understanding of Alzheimer disease pathogenesis, we have yet to identify disease-modifying therapeutics capable of substantially altering the clinical course of this prevalent neurodegenerative disease. In this short review, we discuss 2 approaches that are currently being tested clinically (gamma-secretase inhibition and gamma-secretase modulation) and emphasize the significant differences between these 2 therapeutic approaches. We also discuss certain genetic- and biomarker-based translational and clinical trial paradigms that may assist in developing a useful therapeutic agent. Arch Neurol. 2012;69(10):1255-1258. Published online July 16, 2012. doi:10.1001/archneurol.2012.540
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available